Pricing Supplement No. 133 Dated June 14, 2000
(To Prospectus Supplement dated September 17, 1999
and Prospectus dated September 17, 1999)
Pursuant to Rule 424(b)(3)
Registration Statement No. 333-85283
J.P. Morgan & Co. Incorporated
60 Wall Street
New York, NY 10260-0060
(1-212) 483-2323
Medium-Term Notes, Series A
(Fixed Rate Notes)
Principal Amount: $5,000,000
If principal amount is stated in other than
U.S. dollars, equivalent amount in U.S. dollars: N/A
CUSIP: 61687Y EQ6
Trade Date: June 14, 2000
Settlement Date: July 12, 2000
Maturity Date: July 12, 2005
Price to Public (Issue Price): Varying prices relating to
prevailing market prices.
Net Proceeds to Issuer: $5,000,000 (100%)
Interest Rate (per annum): 7.290%
Interest Payment Date: January 12th and July 12th of each
year, commencing January 12, 2001 (subject to Business Day
convention described in the Prospectus Supplement).
Record Date(s): (X) The fifteenth day (whether or not a
Business Day) next preceding each Interest Payment Date.
( ) Other:
Day Count Basis: (X) 30/360
( ) Actual/360
Form: (X) Book-Entry Note (DTC)
( ) Certificated Note
Redemption:
(X) The Notes may not be redeemed prior to stated maturity.
( ) The Notes may be redeemed.
Optional Redemption Date(s): N/A
Initial Redemption Date: N/A
Initial Redemption Percentage: N/A
Annual Redemption Percentage Reduction: N/A
Modified Payment Upon Acceleration: N/A
Sinking Fund: None
Right of Payment:
( ) Subordinated (X) Unsubordinated
Original Issue Discount: N/A
Amount of OID: N/A
Yield to Maturity: N/A
Interest Accrual Date: N/A
Initial Accrual Period OID: N/A
Amortization Schedule: N/A
Denominations: $250,000 with $50,000 integral multiples thereafter.
Plan of Distribution:
J.P. Morgan Securities Inc. has acted as Agent on
behalf of the Company. The Company has agreed to indemnify
the Agent against certain liabilities, including liabilities
under the Securities Act of 1933, as amended.
Additional Terms:
CAPITALIZED TERMS USED IN THIS PRICING SUPPLEMENT WHICH ARE
DEFINED IN THE PROSPECTUS SUPPLEMENT OR THE PROSPECTUS SHALL
HAVE THE MEANINGS ASSIGNED TO THEM IN THE PROSPECTUS
SUPPLEMENT OR THE PROSPECTUS.
